Enabling Rapid IND Delivery Through Strategic CMC Development of a PD-1/VEGF Bispecific Antibody

• Accelerating biologics CMC timelines through strategic, risk-based development approaches
• Balancing purification efficiency, manufacturability, and product variant control
• De-risking late-stage development through early product and process understanding

Speakers:

Ying Huang

Vice President, CMC Biologics

Crescent Biopharma